Lumiracoxib (Novartis) |
| |
| Authors: | Ding Changhai Jones Graeme |
| |
| Affiliation: | Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart 7000, Tasmania, Australia. chding@utas.edu.au |
| |
| Abstract: | Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
